NewcelX Ltd. (NCEL)
NASDAQ: NCEL · Real-Time Price · USD
3.800
+0.250 (7.04%)
At close: Jun 26, 2026, 4:00 PM EDT
3.640
-0.160 (-4.21%)
After-hours: Jun 26, 2026, 4:10 PM EDT
NewcelX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
19.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Palatin Technologies | 12.88M |
| Marker Therapeutics | 3.55M |
| Lipocine | 2.00M |
| Longeveron | 1.22M |
| Pluri | 1.08M |
| VYNE Therapeutics | 454.00K |
| Allarity Therapeutics | 345.00K |
NCEL News
- 12 days ago - NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - GlobeNewsWire
- 4 weeks ago - NewcelX submits NCEL-101 pre-investigational new drug briefing package to FDA - TheFly
- 4 weeks ago - NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes - GlobeNewsWire
- 6 weeks ago - NewcelX files to sell 2.26M common shares for holders - TheFly
- 2 months ago - NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 - GlobeNewsWire
- 2 months ago - NewcelX announces release of updated presentation on Type 1 Diabetes program - TheFly
- 2 months ago - NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference - GlobeNewsWire
- 3 months ago - NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing - GlobeNewsWire